Pulse Biosciences, Inc (NASDAQ:PLSE) Stock Now Rated “Moderate Buy” by Wall Street Brokerages

Shares of Pulse Biosciences, Inc (NASDAQ:PLSE) have received an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $53.20.

Several equities research analysts recently weighed in on the company. Canaccord Genuity Group boosted their target price on Pulse Biosciences from $43.00 to $58.00 and gave the stock a “buy” rating in a report on Tuesday, October 6th. Wall Street Zen upgraded Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, September 6th. Freedom Capital upgraded Pulse Biosciences to a “strong-buy” rating in a report on Wednesday, September 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Finally, Mizuho set a $45.00 price target on shares of Pulse Biosciences in a research report on Monday, August 10th.

Insider Activity

In other news, COO Liane Teplitsky bought 1,001 shares of the stock in a transaction that occurred on Tuesday, September 1st. The shares were acquired at an average cost of $49.95 per share, for a total transaction of $49,999.95. Following the purchase, the chief operating officer owned 4,095 shares of the company’s stock, valued at $204,545.25. This represents a 32.35% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Over the last ninety days, insiders have acquired 4,095 shares of company stock worth $199,931. 74.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of PLSE. Formula Growth Ltd. bought a new stake in Pulse Biosciences during the second quarter valued at about $832,000. Panoramic Capital LLC acquired a new stake in shares of Pulse Biosciences in the second quarter valued at about $2,719,000. Bank of America Corp DE bought a new position in shares of Pulse Biosciences in the second quarter worth about $40,115,000. Jupiter Topco LLC bought a new position in shares of Pulse Biosciences in the second quarter worth about $241,000. Finally, Osterweis Capital Management Inc. bought a new position in shares of Pulse Biosciences in the second quarter worth about $28,000. Institutional investors and hedge funds own 76.95% of the company’s stock.

Pulse Biosciences Price Performance

NASDAQ PLSE opened at $52.45 on Tuesday. Pulse Biosciences has a fifty-two week low of $12.56 and a fifty-two week high of $58.90. The stock’s 50-day moving average is $49.26 and its two-hundred day moving average is $33.72. The firm has a market cap of $3.71 billion, a P/E ratio of -44.45 and a beta of 1.57.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). The company had revenue of $0.43 million during the quarter, compared to analyst estimates of $0.53 million. Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. On average, equities analysts expect that Pulse Biosciences will post -1.29 EPS for the current year.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a medical technology company developing bioelectric therapies based on its proprietary Nano-Pulse Stimulation (NPS) technology. The platform delivers short, nonthermal electrical pulses that temporarily affect cell membranes and are designed to selectively target unwanted cells while preserving surrounding tissue.

The company’s lead commercial product is the CellFX System, a dermatology platform designed to treat certain benign skin lesions and other dermatologic conditions using NPS technology.